Evidence is mounting that molecular mechanisms underlie gut dysfunction and symptom generation in IBS. Although it is still an uphill struggle, this mounting evidence is a good starting point for the discovery of one or more IBS biomarkers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Atkinson, A. J. Jr et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89–95 (2001).
Camilleri, M. et al. Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterol. Motil. http://dx.doi.org/10.1111/nmo.12421.
Peery, A. F. et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 143, 1179–1187 (2012).
Barbara, G. & Stanghellini, V. Biomarkers in IBS: when will they replace symptoms for diagnosis and management? Gut 58, 1571–1575 (2009).
Camilleri, M. Peripheral mechanisms in irritable bowel syndrome. N. Engl. J. Med. 367, 1626–1635 (2012).
Barbara, G. et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126, 693–702 (2004).
Rajilic-Stojanovic, M. et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141, 1792–1801 (2011).
Jeffery, I. B. et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 61, 997–1006 (2012).
Lembo, A. J. et al. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment. Pharmacol. Ther. 29, 834–842 (2009).
Jones, M. P. et al. A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. Aliment. Pharmacol. Ther. 39, 426–437 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Barbara, G. Biomarkers for IBS: ready for prime time?. Nat Rev Gastroenterol Hepatol 12, 9–10 (2015). https://doi.org/10.1038/nrgastro.2014.217
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.217
